Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST cr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Liver Cancer Association
2025-03-01
|
| Series: | Journal of Liver Cancer |
| Subjects: | |
| Online Access: | http://e-jlc.org/upload/pdf/jlc-2024-09-26.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849733577880633344 |
|---|---|
| author | Pramod Kumar Pradeep Krishna Rohit Maidur Naveen Chandrashekhar Suresh Raghavaiah |
| author_facet | Pramod Kumar Pradeep Krishna Rohit Maidur Naveen Chandrashekhar Suresh Raghavaiah |
| author_sort | Pramod Kumar |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST criteria. The treatment duration is until disease progression or unacceptable side effects occur. Long-term continuation can cause potential toxicities and a substantial financial burden, making early treatment discontinuation a viable option. This report describes durable CR after discontinuing atezo-bev treatment in three patients with HCC and PVTT. |
| format | Article |
| id | doaj-art-2306cd19429f41cd917fd387ae38ac5c |
| institution | DOAJ |
| issn | 2288-8128 2383-5001 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Korean Liver Cancer Association |
| record_format | Article |
| series | Journal of Liver Cancer |
| spelling | doaj-art-2306cd19429f41cd917fd387ae38ac5c2025-08-20T03:08:00ZengKorean Liver Cancer AssociationJournal of Liver Cancer2288-81282383-50012025-03-0125113413710.17998/jlc.2024.09.26580Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first reportPramod Kumar0Pradeep Krishna1Rohit Maidur2Naveen Chandrashekhar3Suresh Raghavaiah4 Department of Hepatology, Gleneagles BGS Hospital, Bengaluru, India Department of Liver Transplantation Surgery, Gleneagles BGS Hospital, Bengaluru, India Department of Medical Gastroenterology, SDM College of Medical Sciences and Hospital, Dharwad, India Department of Interventional Radiology, Gleneagles BGS Hospital, Bengaluru, India Department of Liver Transplantation Surgery, Gleneagles BGS Hospital, Bengaluru, IndiaHepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST criteria. The treatment duration is until disease progression or unacceptable side effects occur. Long-term continuation can cause potential toxicities and a substantial financial burden, making early treatment discontinuation a viable option. This report describes durable CR after discontinuing atezo-bev treatment in three patients with HCC and PVTT.http://e-jlc.org/upload/pdf/jlc-2024-09-26.pdfliver cirrhosiscarcinoma, hepatocellularimmunotherapyliver transplantationhepatitis c |
| spellingShingle | Pramod Kumar Pradeep Krishna Rohit Maidur Naveen Chandrashekhar Suresh Raghavaiah Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report Journal of Liver Cancer liver cirrhosis carcinoma, hepatocellular immunotherapy liver transplantation hepatitis c |
| title | Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report |
| title_full | Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report |
| title_fullStr | Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report |
| title_full_unstemmed | Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report |
| title_short | Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report |
| title_sort | durable complete response after discontinuation of atezolizumab bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis the first report |
| topic | liver cirrhosis carcinoma, hepatocellular immunotherapy liver transplantation hepatitis c |
| url | http://e-jlc.org/upload/pdf/jlc-2024-09-26.pdf |
| work_keys_str_mv | AT pramodkumar durablecompleteresponseafterdiscontinuationofatezolizumabbevacizumabtherapyinpatientswithhepatocellularcarcinomawithportalveintumorthrombosisthefirstreport AT pradeepkrishna durablecompleteresponseafterdiscontinuationofatezolizumabbevacizumabtherapyinpatientswithhepatocellularcarcinomawithportalveintumorthrombosisthefirstreport AT rohitmaidur durablecompleteresponseafterdiscontinuationofatezolizumabbevacizumabtherapyinpatientswithhepatocellularcarcinomawithportalveintumorthrombosisthefirstreport AT naveenchandrashekhar durablecompleteresponseafterdiscontinuationofatezolizumabbevacizumabtherapyinpatientswithhepatocellularcarcinomawithportalveintumorthrombosisthefirstreport AT sureshraghavaiah durablecompleteresponseafterdiscontinuationofatezolizumabbevacizumabtherapyinpatientswithhepatocellularcarcinomawithportalveintumorthrombosisthefirstreport |